SG11201909019SA - Methods of treatment using a jak inhibitor compound - Google Patents
Methods of treatment using a jak inhibitor compoundInfo
- Publication number
- SG11201909019SA SG11201909019SA SG11201909019SA SG11201909019SA SG 11201909019S A SG11201909019S A SG 11201909019SA SG 11201909019S A SG11201909019S A SG 11201909019SA SG 11201909019S A SG11201909019S A SG 11201909019SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- california
- pct
- methods
- foster city
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762492568P | 2017-05-01 | 2017-05-01 | |
| PCT/US2018/030140 WO2018204233A1 (en) | 2017-05-01 | 2018-04-30 | Methods of treatment using a jak inhibitor compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909019SA true SG11201909019SA (en) | 2019-10-30 |
Family
ID=62165728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909019S SG11201909019SA (en) | 2017-05-01 | 2018-04-30 | Methods of treatment using a jak inhibitor compound |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10406148B2 (es) |
| EP (1) | EP3609498A1 (es) |
| JP (2) | JP7153031B2 (es) |
| KR (1) | KR102568333B1 (es) |
| CN (1) | CN110573157B (es) |
| AU (1) | AU2018261588A1 (es) |
| BR (1) | BR112019022665A2 (es) |
| CA (1) | CA3059785A1 (es) |
| CL (1) | CL2019003126A1 (es) |
| MX (1) | MX2019012950A (es) |
| PH (1) | PH12019502345A1 (es) |
| RU (1) | RU2764979C2 (es) |
| SG (1) | SG11201909019SA (es) |
| TW (1) | TW201900170A (es) |
| WO (1) | WO2018204233A1 (es) |
| ZA (1) | ZA201906817B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3001542C (en) | 2015-11-03 | 2021-02-16 | Theravance Biopharma R&D Ip, Llc | Jak kinase inhibitor compounds for treatment of respiratory disease |
| PT3592742T (pt) | 2017-03-09 | 2021-07-30 | Theravance Biopharma R&D Ip Llc | Inibidores de jak contendo uma amida heterocíclica com 4 membros |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| BR112019022665A2 (pt) | 2017-05-01 | 2020-05-19 | Theravance Biopharma R&D Ip Llc | métodos de tratamento usando um composto inibidor de jak |
| CN112638902A (zh) | 2018-09-04 | 2021-04-09 | 施万生物制药研发Ip有限责任公司 | 用于制备jak抑制剂的方法及其中间体 |
| US10947229B2 (en) | 2018-09-04 | 2021-03-16 | Theravance Biopharma R&D Ip, Llc | Dimethyl amino azetidine amides as JAK inhibitors |
| ES2955717T3 (es) | 2018-09-04 | 2023-12-05 | Theravance Biopharma R&D Ip Llc | Amidas heterocíclicas de 5 a 7 elementos como inhibidores de JAK |
| CA3113667A1 (en) | 2018-10-29 | 2020-05-07 | Theravance Biopharma R&D Ip, Llc | 2-azabicyclo hexane compound as jak inhibitor |
| EP3934651A1 (en) | 2019-03-05 | 2022-01-12 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| JP2022537318A (ja) * | 2019-06-17 | 2022-08-25 | バイオマルク ファーマシューティカルズ リミテッド | ぶどう膜炎の処置におけるペプチド及びその使用の方法 |
| TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| CN111973599A (zh) * | 2020-08-07 | 2020-11-24 | 杭州邦顺制药有限公司 | 用于眼部疾病治疗的化合物 |
| CN117083273A (zh) * | 2021-03-26 | 2023-11-17 | 施万生物制药研发Ip有限责任公司 | Jak抑制剂化合物的二盐酸盐的晶型 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| AU2004259012C1 (en) | 2003-07-23 | 2012-08-02 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| CA2673125C (en) | 2006-10-19 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| EP2288260A4 (en) | 2008-06-20 | 2013-10-23 | Genentech Inc | TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD |
| WO2010039825A2 (en) * | 2008-10-01 | 2010-04-08 | Array Biopharma Inc. | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| EP2414340A1 (en) | 2009-04-03 | 2012-02-08 | Dainippon Sumitomo Pharma Co., Ltd. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| JP5738292B2 (ja) * | 2009-07-28 | 2015-06-24 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ経路の阻害のための組成物および方法 |
| WO2011084486A1 (en) | 2009-12-21 | 2011-07-14 | Epitherix, Llc | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| EA024026B1 (ru) | 2010-11-25 | 2016-08-31 | Рациофарм Гмбх | Новые соли и полиморфные формы афатиниба |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| CA2926361A1 (en) * | 2013-10-24 | 2015-04-30 | Abbvie Inc. | Jak1 selective inhibitor and uses thereof |
| JP6192839B2 (ja) | 2013-12-05 | 2017-09-06 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、およびピロロ［２，３−ｄ］ピリジニルアクリルアミド |
| WO2015168461A2 (en) | 2014-04-30 | 2015-11-05 | Agilent Technologies, Inc. | Phosphorous protecting groups and methods of preparation and use thereof |
| AU2015260905A1 (en) | 2014-05-14 | 2016-12-01 | Pfizer Inc. | Pyrazolopyridines and pyrazolopyrimidines |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| WO2017077283A1 (en) | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| US10556901B2 (en) | 2015-11-03 | 2020-02-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors |
| CA3001542C (en) | 2015-11-03 | 2021-02-16 | Theravance Biopharma R&D Ip, Llc | Jak kinase inhibitor compounds for treatment of respiratory disease |
| PT3592742T (pt) | 2017-03-09 | 2021-07-30 | Theravance Biopharma R&D Ip Llc | Inibidores de jak contendo uma amida heterocíclica com 4 membros |
| SG11201909376TA (en) | 2017-05-01 | 2019-11-28 | Theravance Biopharma R&D Ip Llc | Crystalline forms of a jak inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| BR112019022665A2 (pt) | 2017-05-01 | 2020-05-19 | Theravance Biopharma R&D Ip Llc | métodos de tratamento usando um composto inibidor de jak |
-
2018
- 2018-04-30 BR BR112019022665A patent/BR112019022665A2/pt active Search and Examination
- 2018-04-30 CA CA3059785A patent/CA3059785A1/en active Pending
- 2018-04-30 US US15/966,438 patent/US10406148B2/en active Active
- 2018-04-30 JP JP2019559282A patent/JP7153031B2/ja active Active
- 2018-04-30 TW TW107114724A patent/TW201900170A/zh unknown
- 2018-04-30 RU RU2019138463A patent/RU2764979C2/ru active
- 2018-04-30 WO PCT/US2018/030140 patent/WO2018204233A1/en unknown
- 2018-04-30 MX MX2019012950A patent/MX2019012950A/es unknown
- 2018-04-30 KR KR1020197035392A patent/KR102568333B1/ko active IP Right Grant
- 2018-04-30 AU AU2018261588A patent/AU2018261588A1/en active Pending
- 2018-04-30 EP EP18724752.3A patent/EP3609498A1/en active Pending
- 2018-04-30 CN CN201880028764.8A patent/CN110573157B/zh active Active
- 2018-04-30 SG SG11201909019S patent/SG11201909019SA/en unknown
-
2019
- 2019-07-30 US US16/525,859 patent/US10548886B2/en active Active
- 2019-10-15 PH PH12019502345A patent/PH12019502345A1/en unknown
- 2019-10-16 ZA ZA2019/06817A patent/ZA201906817B/en unknown
- 2019-10-30 CL CL2019003126A patent/CL2019003126A1/es unknown
- 2019-12-18 US US16/718,543 patent/US11160800B2/en active Active
-
2021
- 2021-09-28 US US17/449,136 patent/US11786517B2/en active Active
-
2022
- 2022-06-15 JP JP2022096560A patent/JP2022120147A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ758109A (en) | 2021-09-24 |
| KR102568333B1 (ko) | 2023-08-18 |
| MX2019012950A (es) | 2019-12-16 |
| ZA201906817B (en) | 2021-10-27 |
| US11786517B2 (en) | 2023-10-17 |
| RU2019138463A (ru) | 2021-06-02 |
| US11160800B2 (en) | 2021-11-02 |
| JP2020518579A (ja) | 2020-06-25 |
| TW201900170A (zh) | 2019-01-01 |
| US20200121669A1 (en) | 2020-04-23 |
| CN110573157B (zh) | 2023-04-04 |
| PH12019502345A1 (en) | 2020-12-07 |
| RU2019138463A3 (es) | 2021-08-03 |
| EP3609498A1 (en) | 2020-02-19 |
| US10406148B2 (en) | 2019-09-10 |
| CN110573157A (zh) | 2019-12-13 |
| WO2018204233A1 (en) | 2018-11-08 |
| US20180311226A1 (en) | 2018-11-01 |
| RU2764979C2 (ru) | 2022-01-24 |
| CA3059785A1 (en) | 2018-11-08 |
| US20220008403A1 (en) | 2022-01-13 |
| CL2019003126A1 (es) | 2020-01-24 |
| JP2022120147A (ja) | 2022-08-17 |
| AU2018261588A1 (en) | 2019-10-31 |
| JP7153031B2 (ja) | 2022-10-13 |
| US10548886B2 (en) | 2020-02-04 |
| BR112019022665A2 (pt) | 2020-05-19 |
| US20190350916A1 (en) | 2019-11-21 |
| KR20190140062A (ko) | 2019-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909019SA (en) | Methods of treatment using a jak inhibitor compound | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201804294WA (en) | Tank-binding kinase inhibitor compounds | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201900596XA (en) | Cannabis composition | |
| SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201808708RA (en) | Heterocyclic amides useful as protein modulators | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof |